Lantheus Holdings, Inc. (NASDAQ:LNTH) Shares Sold by New York State Teachers Retirement System

New York State Teachers Retirement System lowered its holdings in Lantheus Holdings, Inc. (NASDAQ:LNTH - Free Report) by 7.8% during the first quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 84,468 shares of the medical equipment provider's stock after selling 7,100 shares during the quarter. New York State Teachers Retirement System owned 0.12% of Lantheus worth $8,244,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in LNTH. Jones Financial Companies Lllp raised its position in Lantheus by 108.3% in the fourth quarter. Jones Financial Companies Lllp now owns 2,273 shares of the medical equipment provider's stock valued at $203,000 after purchasing an additional 1,182 shares during the period. Victory Capital Management Inc. raised its position in Lantheus by 13.4% in the fourth quarter. Victory Capital Management Inc. now owns 87,130 shares of the medical equipment provider's stock valued at $7,795,000 after purchasing an additional 10,297 shares during the period. Assetmark Inc. raised its position in Lantheus by 10.0% in the fourth quarter. Assetmark Inc. now owns 69,059 shares of the medical equipment provider's stock valued at $6,178,000 after purchasing an additional 6,257 shares during the period. Arizona State Retirement System raised its position in Lantheus by 0.9% in the fourth quarter. Arizona State Retirement System now owns 20,137 shares of the medical equipment provider's stock valued at $1,801,000 after purchasing an additional 178 shares during the period. Finally, Raymond James Financial Inc. acquired a new stake in shares of Lantheus in the fourth quarter valued at $36,183,000. Hedge funds and other institutional investors own 99.06% of the company's stock.

Analyst Ratings Changes

A number of brokerages have recently weighed in on LNTH. Wall Street Zen raised Lantheus from a "hold" rating to a "buy" rating in a research note on Thursday, May 8th. B. Riley dropped their price objective on Lantheus from $122.00 to $109.00 and set a "buy" rating for the company in a research note on Monday, June 23rd. Finally, Truist Financial dropped their price objective on Lantheus from $127.00 to $117.00 and set a "buy" rating for the company in a research note on Thursday, May 8th. Seven investment analysts have rated the stock with a buy rating, According to MarketBeat, the stock currently has an average rating of "Buy" and an average price target of $130.50.

Insider Activity

In other news, Director Mary Anne Heino sold 26,066 shares of the company's stock in a transaction dated Monday, June 2nd. The stock was sold at an average price of $76.83, for a total transaction of $2,002,650.78. Following the completion of the transaction, the director directly owned 318,650 shares of the company's stock, valued at approximately $24,481,879.50. This represents a 7.56% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Corporate insiders own 2.00% of the company's stock.

Lantheus Stock Down 0.5%

LNTH traded down $0.41 on Friday, hitting $79.21. 329,518 shares of the company were exchanged, compared to its average volume of 1,022,632. Lantheus Holdings, Inc. has a twelve month low of $73.11 and a twelve month high of $126.89. The company has a market cap of $5.48 billion, a price-to-earnings ratio of 22.50 and a beta of 0.12. The company has a current ratio of 5.74, a quick ratio of 5.46 and a debt-to-equity ratio of 0.49. The firm has a 50-day moving average price of $82.57 and a two-hundred day moving average price of $90.23.

Lantheus (NASDAQ:LNTH - Get Free Report) last released its earnings results on Wednesday, May 7th. The medical equipment provider reported $1.53 EPS for the quarter, missing the consensus estimate of $1.64 by ($0.11). Lantheus had a return on equity of 36.99% and a net margin of 16.55%. The company had revenue of $372.76 million for the quarter, compared to analyst estimates of $377.37 million. During the same period in the previous year, the firm earned $1.69 earnings per share. The company's revenue for the quarter was up .8% compared to the same quarter last year. On average, equities analysts predict that Lantheus Holdings, Inc. will post 6.01 earnings per share for the current year.

Lantheus Company Profile

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.